|
1
|
Lozar T, Gersak K, Cemazar M, Kuhar CG and
Jesenko T: The biology and clinical potential of circulating tumor
cells. Radiol Oncol. 53:131–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deng Z, Wu S, Wang Y and Shi D:
Circulating tumor cell isolation for cancer diagnosis and
prognosis. EBioMedicine. 83:1042372022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen SJ, Punt CJ, Iannotti N, Saidman BH,
Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et
al: Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka F, Yoneda K, Kondo N, Hashimoto M,
Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T,
et al: Circulating tumor cell as a diagnostic marker in primary
lung cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 40:e1086472021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu G, Lu Z, Li C, Huang X and Luo Q:
Prognostic and therapeutic significance of circulating tumor cell
phenotype detection based on epithelial-mesenchymal transition
markers in early and midstage colorectal cancer first-line
chemotherapy. Comput Math Methods Med. 2021:22945622021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao Y, Fan WH, Song Z, Lou H and Kang X:
Comparison of circulating tumor cell (CTC) detection rates with
epithelial cell adhesion molecule (EpCAM) and cell surface vimentin
(CSV) antibodies in different solid tumors: A retrospective study.
PeerJ. 9:e107772021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohnaga T, Shimada Y, Moriyama M, Kishi H,
Obata T, Takata K, Okumura T, Nagata T, Muraguchi A and Tsukada K:
Polymeric microfluidic devices exhibiting sufficient capture of
cancer cell line for isolation of circulating tumor cells. Biomed
Microdevices. 15:611–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chikaishi Y, Yoneda K, Ohnaga T and Tanaka
F: EpCAM-independent capture of circulating tumor cells with a
‘universal CTC-chip’. Oncol Rep. 37:77–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kuwata T, Yoneda K, Mori M, Kanayama M,
Kuroda K, Kaneko MK, Kato Y and Tanaka F: Detection of circulating
tumor cells (CTCs) in malignant pleural mesothelioma (MPM) with the
‘universal’ CTC-chip and an anti-podoplanin antibody NZ-1.2. Cells.
9:8882020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanayama M, Oyama R, Mori M, Taira A,
Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, et
al: Novel circulating tumor cell-detection chip combining
conventional podoplanin and EGFR antibodies for all histological
malignant pleural mesothelioma. Oncol Lett. 22:5222021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoneda K, Kuwata T, Chikaishi Y, Mori M,
Kanayama M, Takenaka M, Oka S, Hirai A, Imanishi N, Kuroda K, et
al: Detection of circulating tumor cells with a novel microfluidic
system in malignant pleural mesothelioma. Cancer Sci. 110:726–733.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanayama M, Kuwata T, Mori M, Nemoto Y,
Nishizawa N, Oyama R, Matsumiya H, Taira A, Shinohara S, Takenaka
M, et al: Prognostic impact of circulating tumor cells detected
with the microfluidic ‘universal CTC-chip’ for primary lung cancer.
Cancer Sci. 113:1028–1037. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Satelli A, Mitra A, Brownlee Z, Xia X,
Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH and Li S:
Epithelial-mesenchymal transitioned circulating tumor cells capture
for detecting tumor progression. Clin Cancer Res. 21:899–906. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Satelli A, Batth I, Brownlee Z, Mitra A,
Zhou S, Noh H, Rojas CR, Li H, Meng QH and Li S: EMT circulating
tumor cells detected by cell-surface vimentin are associated with
prostate cancer progression. Oncotarget. 8:49329–49337. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei T, Zhang X, Zhang Q, Yang J, Chen Q,
Wang J, Li X, Chen J, Ma T, Li G, et al: Vimentin-positive
circulating tumor cells as a biomarker for diagnosis and treatment
monitoring in patients with pancreatic cancer. Cancer Lett.
452:237–243. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Zhu YZ, Xu L, Han T, Luan J, Li X,
Liu Y, Wang Z, Liu Q, Kong X, et al: Exploring new frontiers: Cell
surface vimentin as an emerging marker for circulating tumor cells
and a promising therapeutic target in advanced gastric cancer. J
Exp Clin Cancer Res. 43:1292024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riegger J and Brenner RE: Increase of cell
surface vimentin is associated with vimentin network disruption and
subsequent stress-induced premature senescence in human
chondrocytes. Elife. 12:e914532023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Markou A, Tzanikou E and Lianidou E: The
potential of liquid biopsy in the management of cancer patients.
Semin Cancer Biol. 84:69–79. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alix-Panabières C, Marchetti D and Lang
JE: Liquid biopsy: From concept to clinical application. Sci Rep.
13:216852023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strouhalova K, Přechová M, Gandalovičová
A, Brábek J, Gregor M and Rosel D: Vimentin intermediate filaments
as potential target for cancer treatment. Cancers (Basel).
12:1842020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Usman S, Waseem NH, Nguyen TKN, Mohsin S,
Jamal A, Teh MT and Waseem A: Vimentin is at the heart of
epithelial mesenchymal transition (EMT) mediated metastasis.
Cancers (Basel). 13:49852021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paulin D, Lilienbaum A, Kardjian S,
Agbulut O and Li Z: Vimentin: Regulation and pathogenesis.
Biochimie. 197:96–112. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramos I, Stamatakis K, Oeste CL and
Pérez-Sala D: Vimentin as a multifaceted player and potential
therapeutic target in viral infections. Int J Mol Sci. 21:46752020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xie X, Wang L, Wang X, Fan WH, Qin Y, Lin
X, Xie Z, Liu M, Ouyang M, Li S and Zhou C: Evaluation of cell
surface vimentin positive circulating tumor cells as a diagnostic
biomarker for lung cancer. Front Oncol. 11:6726872021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu J, Yang M, Peng T, Liu Y and Cao Y:
Evaluation of cell surface vimentin positive circulating tumor
cells as a prognostic biomarker for stage III/IV colorectal cancer.
Sci Rep. 13:187912023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Batth IS, Dao L, Satelli A, Mitra A, Yi S,
Noh H, Li H, Brownlee Z, Zhou S, Bond J, et al: Cell surface
vimentin-positive circulating tumor cell-based relapse prediction
in a long-term longitudinal study of postremission neuroblastoma
patients. Int J Cancer. 147:3550–3559. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Noh H, Zhao Q, Yan J, Kong LY,
Gabrusiewicz K, Hong S, Xia X, Heimberger AB and Li S: Cell surface
vimentin-targeted monoclonal antibody 86C increases sensitivity to
temozolomide in glioma stem cells. Cancer Lett. 433:176–185. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Batth IS and Li S: Discovery of
cell-surface vimentin (CSV) as a sarcoma target and development of
CSV-targeted IL12 immune therapy. Adv Exp Med Biol. 1257:169–178.
2020. View Article : Google Scholar : PubMed/NCBI
|
